Free Trial

Astra Zeneca (AZN: A2 / A): 2Q24 Results

HEALTHCARE
  • Solid beat and Raises guidance
  • Total Revenue and Core EPS expected to increase mid teens %
  • 1H revenues up 18% at Constant Exchange Rates
  • Revenue 2Q $12,988M
  • 2Q EBITDA $4,025M
  • Net Debt $26.3b - increased from $22.5b
  • Issued 4 bonds in 2024, no immediate need to finance more.
  • Building a $1.5b manufacturing facility in Singapore for Antibody Drug Conjugates
  • Completed acquisitions of Fusion Pharma and Amolyt.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.